News
Major boost for US maternal health research project
A US university has received a grant of almost US$12m to develop a new maternal health research centre.
The University of Arkansas for Medical Sciences (UAMS) Institute for Community Health Innovation will expand research for maternal health in Arkansas by establishing the Maternal and Reproductive Community Health Excellence (MaRCH) research centre funded through National Institutes of Health’s Centers of Biomedical Research Excellence (COBRE).
The MaRCH research centre will focus on training and supporting new researchers who develop innovations in maternal and reproductive health in Arkansas.
The grant, worth around US$11.7m over five years, will support at least three new maternal and reproductive health researchers each year.
This is the one of the first COBRE grants in the US focused on maternal health.
Additionally, as part of the project, the institute will bring together the top researchers and thought leaders from across the nation for a conference in spring 2026 on maternal and reproductive health.
“This award will help accelerate improvements in maternal and reproductive health in Arkansas,” said Pearl McElfish, director of the UAMS Institute for Community Health Innovation and principal investigator of the MaRCH research centre.
“By building a pipeline of researchers and implementing data-driven, community-focused solutions, we’re laying the foundation for healthier futures for mothers and families, especially in rural communities that need it most.”
The institute implements numerous research and program initiatives to improve access to maternal health care across Arkansas, particularly in maternal health deserts. Institute-led programs such as Healthy Start and group prenatal care provide one-on-one case management and education services to new and existing mothers. The institute is also training doulas and perinatal community health workers across the state, while institute researchers study the impact of unique interventions such as remote monitoring, digital health, food as medicine programs, and more for pregnant women.
Earlier this summer, the institute published a study in the American Journal of Obstetrics and Gynecology Global Report that detailed benefits that postpartum mothers experienced through digital health services, such as higher rates of screenings for abuse and postpartum depression.
The study also highlighted the importance of reducing excess gestational weight gain as an important way to reduce cesarean deliveries.
“Improving maternal health is one of the most urgent public health priorities in Arkansas right now,” McElfish said. “We are proud to pioneer real-world solutions that drive meaningful change for women in rural and underserved communities. Every mother deserves access to safe, quality care, and our work is helping to make that a reality across Arkansas.”
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






